Is Sarepta Therapeutics Stock a Good Investment?
Sarepta Therapeutics Investment Advice | SRPT |
- Examine Sarepta Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Sarepta Therapeutics' leadership team and their track record. Good management can help Sarepta Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Sarepta Therapeutics' business and its evolving consumer preferences.
- Compare Sarepta Therapeutics' performance and market position to its competitors. Analyze how Sarepta Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Sarepta Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Sarepta Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Sarepta Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Sarepta Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Sarepta Therapeutics Stock
Researching Sarepta Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 97.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.37. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sarepta Therapeutics recorded a loss per share of 2.64. The entity had not issued any dividends in recent years. The firm had 1:6 split on the 12th of July 2012.
To determine if Sarepta Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sarepta Therapeutics' research are outlined below:
| Sarepta Therapeutics generated a negative expected return over the last 90 days | |
| Sarepta Therapeutics has high historical volatility and very poor performance | |
| Sarepta Therapeutics currently holds about 2.07 B in cash with (205.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 23.61, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: Sarepta Therapeutics Announces Restructuring and ELEVIDYS Black Box Warning, EMA Recommends Refusal of Marketing Authorization, Securities Class Action Pending Hagens Berman |
Sarepta Therapeutics Quarterly Cash And Short Term Investments |
|
Sarepta Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Sarepta Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Sarepta Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Sarepta Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Sarepta Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2018-03-01 | 2017-12-31 | -0.32 | -0.37 | -0.05 | 15 | ||
2024-08-07 | 2024-06-30 | 0.01 | 0.07 | 0.06 | 600 | ||
2010-11-09 | 2010-09-30 | -0.36 | -0.42 | -0.06 | 16 | ||
2008-03-12 | 2007-12-31 | -0.48 | -0.42 | 0.06 | 12 | ||
2017-10-25 | 2017-09-30 | -0.85 | -0.76 | 0.09 | 10 | ||
2014-08-07 | 2014-06-30 | -0.76 | -0.85 | -0.09 | 11 | ||
2009-11-09 | 2009-09-30 | -0.39 | -0.48 | -0.09 | 23 | ||
2008-11-10 | 2008-09-30 | -0.39 | -0.48 | -0.09 | 23 |
Know Sarepta Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sarepta Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sarepta Therapeutics backward and forwards among themselves. Sarepta Therapeutics' institutional investor refers to the entity that pools money to purchase Sarepta Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2025-03-31 | 1.8 M | Deutsche Bank Ag | 2025-03-31 | 1.7 M | Ubs Group Ag | 2025-03-31 | 1.4 M | Groupama Asset Management | 2025-03-31 | 1.3 M | Ecor1 Capital, Llc | 2025-03-31 | 1.3 M | Aberdeen Group Plc | 2025-06-30 | 1.2 M | Erste Asset Management Gmbh | 2025-03-31 | 1.1 M | Pictet Asset Manangement Sa | 2025-03-31 | 937 K | Casdin Capital, Llc | 2025-03-31 | 900.8 K | Blackrock Inc | 2025-03-31 | 9.9 M | Capital Research & Mgmt Co - Division 3 | 2025-03-31 | 9.1 M |
Sarepta Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.56 B.Market Cap |
|
Sarepta Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.06 | 0.06 | |
| Return On Capital Employed | 0.07 | 0.07 | |
| Return On Assets | 0.06 | 0.06 | |
| Return On Equity | 0.15 | 0.16 |
Determining Sarepta Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Sarepta Therapeutics is a good buy. For example, gross profit margin measures Sarepta Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sarepta Therapeutics' profitability and make more informed investment decisions.
Sarepta Therapeutics' Earnings Breakdown by Geography
Please note, the imprecision that can be found in Sarepta Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Sarepta Therapeutics. Check Sarepta Therapeutics' Beneish M Score to see the likelihood of Sarepta Therapeutics' management manipulating its earnings.
Evaluate Sarepta Therapeutics' management efficiency
Sarepta Therapeutics has return on total asset (ROA) of (0.0219) % which means that it has lost $0.0219 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2361) %, meaning that it created substantial loss on money invested by shareholders. Sarepta Therapeutics' management efficiency ratios could be used to measure how well Sarepta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.06 in 2025. Return On Capital Employed is likely to gain to 0.07 in 2025. At this time, Sarepta Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 4.2 B in 2025, whereas Non Current Liabilities Other is likely to drop slightly above 46.7 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 16.07 | 16.87 | |
| Tangible Book Value Per Share | 15.79 | 16.58 | |
| Enterprise Value Over EBITDA | 35.43 | 37.20 | |
| Price Book Value Ratio | 7.57 | 6.75 | |
| Enterprise Value Multiple | 35.43 | 37.20 | |
| Price Fair Value | 7.57 | 6.75 | |
| Enterprise Value | 10.8 B | 11.3 B |
Effective leadership at Sarepta Therapeutics drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Beta 0.455 |
Basic technical analysis of Sarepta Stock
As of the 4th of August, Sarepta Therapeutics has the Coefficient Of Variation of (633.37), variance of 88.56, and Risk Adjusted Performance of (0.12). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sarepta Therapeutics, as well as the relationship between them.Sarepta Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sarepta Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sarepta Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sarepta Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sarepta Therapeutics' Outstanding Corporate Bonds
Sarepta Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Sarepta Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Sarepta bonds can be classified according to their maturity, which is the date when Sarepta Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Sarepta Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Sarepta Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (1.57) | |||
| Mean Deviation | 5.3 | |||
| Coefficient Of Variation | (633.37) | |||
| Standard Deviation | 9.41 | |||
| Variance | 88.56 | |||
| Information Ratio | (0.17) | |||
| Jensen Alpha | (1.59) | |||
| Total Risk Alpha | (2.73) | |||
| Treynor Ratio | (1.58) | |||
| Maximum Drawdown | 55.44 | |||
| Value At Risk | (21.45) | |||
| Potential Upside | 9.87 | |||
| Skewness | (2.07) | |||
| Kurtosis | 7.81 |
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (1.57) | |||
| Mean Deviation | 5.3 | |||
| Coefficient Of Variation | (633.37) | |||
| Standard Deviation | 9.41 | |||
| Variance | 88.56 | |||
| Information Ratio | (0.17) | |||
| Jensen Alpha | (1.59) | |||
| Total Risk Alpha | (2.73) | |||
| Treynor Ratio | (1.58) | |||
| Maximum Drawdown | 55.44 | |||
| Value At Risk | (21.45) | |||
| Potential Upside | 9.87 | |||
| Skewness | (2.07) | |||
| Kurtosis | 7.81 |
Consider Sarepta Therapeutics' intraday indicators
Sarepta Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Sarepta Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Sarepta Therapeutics Corporate Filings
| 25th of July 2025 Other Reports | ViewVerify | |
8K | 21st of July 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 19th of May 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 6th of May 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Sarepta Stock media impact
There is far too much social signal, news, headlines, and media speculation about Sarepta Therapeutics that are available to investors today. This information is accessible both publicly - through Sarepta Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Sarepta-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Sarepta Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Sarepta Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Sarepta Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Sarepta Therapeutics alpha.
Sarepta Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Sarepta Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Sarepta Therapeutics Historical Investor Sentiment
Investor biases related to Sarepta Therapeutics' public news can be used to forecast risks associated with an investment in Sarepta. The trend in average sentiment can be used to explain how an investor holding Sarepta can time the market purely based on public headlines and social activities around Sarepta Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Sarepta Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Sarepta Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Sarepta Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Sarepta Therapeutics.
Sarepta Therapeutics Maximum Pain Price Across September 19th 2025 Option Contracts
Sarepta Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Sarepta Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Sarepta Therapeutics' options.
Sarepta Therapeutics Corporate Management
| Ryan JD | General VP | Profile | |
| Will Tilton | Head VP | Profile | |
| William Ciambrone | Ex Operations | Profile | |
| Dallan Murray | Executive Officer | Profile | |
| Rachael Potter | Chief Officer | Profile |
Additional Tools for Sarepta Stock Analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.